Journal Mobile Options
Table of Contents
Vol. 79, No. 1, 2010
Issue release date: December 2009
Psychother Psychosom 2010;79:31–38

Group Psychotherapy of Dysfunctional Fear of Progression in Patients with Chronic Arthritis or Cancer

Herschbach P. · Berg P. · Waadt S. · Duran G. · Engst-Hastreiter U. · Henrich G. · Book K. · Dinkel A.
aDepartment of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, bInstitute for Therapy Research, IFT-Gesundheitsförderung, München, and cRheumatology Rehabilitation Center, Bad Aibling, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: This study investigated the effectiveness of brief psychotherapeutic group interventions in reducing dysfunctional fear of disease progression (FoP). The interventions comprised either cognitive-behavioral group therapy or supportive-experiential group therapy. We tested whether these generic interventions would prove effective in different illness types. Methods: Chronic arthritis in- patients (n = 174) and cancer in-patients (n = 174), respectively, were randomized to receive one of the two interventions. The patients provided data before intervention, at discharge, and at 3 and 12 months of follow-up. FoP was the primary outcome, secondary outcomes were anxiety, depression and quality of life. A treatment-as-usual control group provided data on the primary outcome. Results: Patients with chronic arthritis indicated higher levels of FoP than cancer patients. The results revealed that, compared with no specialized intervention, both group therapies were effective in reducing dysfunctional FoP, but only among cancer patients. The effect sizes were 0.54 (cognitive-behavioral therapy) and 0.50 (supportive experiential therapy). The interventions were not differently effective in reducing the secondary outcomes. Conclusions: Dysfunctional FoP can be effectively targeted with brief group interventions. Psychotherapeutic interventions for reducing FoP should focus on specific illness characteristics.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Barth J, Schumacher M, Herrmann-Lingen C: Depression as a risk factor for mortality in patients with coronary heart diseases: a meta-analysis. Psychosom Med 2004;66:802–813.
  2. Cooke D, Newman S, Sacker A, DeVellis B, Bebbington P, Meltzer H: The impact of physical illnesses on non-psychotic psychiatric morbidity: data from the household survey of psychiatric morbidity in Great Britain. Br J Health Psychol 2007;12:463–471.
  3. Das-Munshi J, Stewart R, Ismail K, Bebbington PE, Jenkins R, Prince MJ: Diabetes, common mental disorders, and disability: findings from the UK National Psychiatric Morbidity Survey. Psychosom Med 2007;69:543–550.
  4. Härter M, Baumeister H, Reuter K, Jacobi F, Höfler M, Bengel J, Wittchen HU: Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 2007;76:354–360.
  5. Mehnert A, Koch U: Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psychooncology 2007;16:181–188.
  6. Surtees PG, Wainwright NWJ, Luben RN, Wareham NJ, Bingham SA, Khaw KT: Depression and ischemic heart disease mortality: evidence from the EPIC-Norfolk United Kingdom prospective cohort study. Am J Psychiatry 2008;165:515–523.
  7. Gurevich M, Devins GM, Rodin GM: Stress response syndromes and cancer: conceptual and assessment issues. Psychosomatics 2002;43:259–281.
  8. Clarke DM, Smith GC, Dowe DL, McKenzie DP: An empirically derived taxonomy of common distress syndromes in the medically ill. J Psychosom Res 2003;54:323–330.
  9. Ketterer MW, Wulsin L, Cao JJ, Schairer J, Hakim A, Hudson M, Keteyian SJ, Khanal S, Clark V, Weaver WD: ‘Major’ depressive disorder, coronary heart disease, and the DSM-IV threshold problem. Psychosomatics 2006;47:50–55.
  10. Fava GA, Mangelli L, Ruini C: Assessment of psychological distress in the setting of medical disease. Psychother Psychosom 2001;70:171–175.
  11. Ferrari S, Galeazzi GM, Mackinnon A, Rigatelli M: Frequent attenders in primary care: impact of medical, psychiatric and psychosomatic diagnoses. Psychother Psychosom 2008;77:306–314.
  12. Sirri L, Grandi S, Fava GA: The Illness Attitude Scales: a clinimetric index for assessing hypochondriacal fears and beliefs. Psychother Psychosom 2008;77:337–350.
  13. De Ridder DTD, Schreurs KMG, Bensing JM: Adaptive tasks, coping and quality of life of chronically ill patients: the cases of Parkinson’s disease and chronic fatigue syndrome. J Health Psychol 1998;3:87–101.
  14. Heijmans M, Rijken M, Foets M, de Ridder D, Schreurs K, Bensing J: The stress of being chronically ill: from disease-specific to task-specific aspects. J Behav Med 2004;27:255–271.
  15. Farrell C, Heaven C, Beaver K, Maguire P: Identifying the concerns of women undergoing chemotherapy. Patient Educ Couns 2005;56:72–77.
  16. Dankert A, Duran G, Engst-Hastreiter U, Keller M, Waadt S, Henrich G, Herschbach P: Progredienzangst bei Patienten mit Tumorerkrankungen, Diabetes mellitus und entzündlich-rheumatischen Erkrankungen. Rehabilitation 2003;42:155–163.
  17. Herschbach P, Keller M, Knight L, Brandl T, Huber B, Henrich G, Marten-Mittag B: Psychological problems of cancer patients: a cancer distress screening with a cancer-specific questionnaire. Br J Cancer 2004;91:504–511.
  18. Lee-Jones C, Humphris G, Dixon R, Hatcher MB: Fear of cancer recurrence – a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology 1997;6:95–105.
  19. Herschbach P, Berg P, Dankert A, Duran G, Engst-Hastreiter U, Waadt S, Keller M, Ukat R, Henrich G: Fear of progression in chronic diseases: psychometric properties of the Fear of Progression Questionnaire. J Psychosom Res 2005;58:505–511.
  20. Vamos M: Psychotherapy in the medically ill: a commentary. Aust NZ J Psychiatry 2006;40:295–309.
  21. Fekete EM, Antoni MH, Schneiderman N: Psychosocial and behavioral interventions for chronic medical conditions. Curr Opin Psychiatry 2007;20:152–157.
  22. Newell SA, Sanson-Fisher RW, Savolainen NJ: Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Natl Cancer Inst 2002;94:558–584.
  23. Uitterhoeve RJ, Vernooy M, Litjens M, Potting K, Bensing J, De Mulder P, van Achterberg T: Psychological interventions for patients with advanced cancer – a systematic review of the literature. Br J Cancer 2004;91:1050–1062.
  24. Williams S, Dale J: The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006;94:372–390.
  25. Crepaz N, Passin WF, Herbst JH, Rama SM, Malow RM, Purcell DW, Wolitski RJ, HIV/AIDS Prevention Research Synthesis Team: Meta-analysis of cognitive-behavioral interventions on HIV-positive persons’ mental health and immune functioning. Health Psychol 2008;27:4–14.
  26. Nezu AM, Nezu CM, Felgoise SH, McClure KS, Houts PS: Project Genesis: assessing the efficacy of problem-solving therapy for distressed adult cancer patients. J Consult Clin Psychol 2003;71:1036–1048.
  27. Penedo FJ, Molton I, Dahn JR, Shen BJ, Kinsinger D, Traeger L, Siegel S, Schneiderman N, Antoni M: A randomized clinical trial of group-based cognitive-behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann Behav Med 2006;31:261–270.
  28. Rhee SH, Parker JC, Smarr KL, Petroski GF, Johnson JC, Hewett JE, Wright GE, Multon KD, Walker SE: Stress management in rheumatoid arthritis: what is the underlying mechanism? Arthritis Care Res 2000;13:435–442.
  29. Kissane DW, Bloch S, Miach P, Smith GC, Seddon A, Keks N: Cognitive-existential group therapy for patients with primary breast cancer – techniques and themes. Psychooncology 1997;6:25–33.
  30. LeMay K, Wilson KG: Treatment of existential distress in life-threatening illness: a review of manualized interventions. Clin Psychol Rev 2008;28:472–493.
  31. Rolland JS: Toward a psychosocial typology of chronic and life-threatening illness. Fam Syst Med 1984;2:245–262.

    External Resources

  32. Alonso J, Ferrer M, Gandek B, Ware JE Jr, Aaronson NK, Mosconi P, Rasmussen NK, Bullinger M, Fukuhara S, Kaasa S, Leplège A, IQOLA Project Group: Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 2004;13:283–298.
  33. Loza E, Abásolo L, Jover JA, Carmona L, EPISER Study Group: Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. J Rheumatol 2008;35:159–165.
  34. Saarni SI, Härkänen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, Lönnqvist J: The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006;15:1403–1414.
  35. Sprangers MAG, de Regt EB, Andries F, van Agt HME, Bijl RV, de Boer JB, Foets M, Hoeymans N, Jacobs AE, Kempen GIJM, Miedema HS, Tijhuis MAR, de Haes HCJM: Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000;53:895–907.
  36. Barlow JH, Wright CC, Turner AP, Bancroft GV: A 12-month follow-up study of self-management training for people with chronic disease: are changes maintained over time? Br J Health Psychol 2005;10:589–599.
  37. Mehnert A, Herschbach P, Berg P, Henrich G, Koch U: Progredienzangst bei Brustkrebspatientinnen – Validierung der Kurzform des Progredienzangstfragebogens PA-F-KF. Z Psychosom Med Psychother 2006;52:274–288.
  38. Herrmann-Lingen C, Buss U, Snaith RP: HADS-D. Hospital and Anxiety Depression Scale – Deutsche Version. Bern, Huber, 1995.
  39. Bullinger M, Kirchberger I: SF-36. Fragebogen zum Gesundheitszustand. Göttingen, Hogrefe, 1998.
  40. Henrich G, Herschbach P: Questions on Life Satisfaction (FLZM) – A short questionnaire for assessing subjective quality of life. Eur J Psychol Assess 2000;16:150–159.

    External Resources

  41. Bordeleau, L, Szalai JP, Ennis M, Leszcz M, Speca M, Sela R, Doll R, Chochinov HM, Navarro M, Arnold A, Pritchard KI, Bezjak A, Llewellyn-Thomas HA, Sawka CA, Goodwin PJ: Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data. J Clin Oncol 2003;21:1944–1951.
  42. Classen CC, Kraemer HC, Blasey C, Giese-Davis J, Koopman C, Palesh OG, Atkinson A, DiMiceli S, Stonisch-Riggs G, Westendorp J, Morrow GR, Spiegel D: Supportive-expressive group therapy for primary breast cancer patients: a randomized prospective multicenter trial. Psychooncology 2008;17:438–447.
  43. Dobkin PL, Da Costa D, Joseph L, Fortin PR, Edworthy S, Barr S, Ensworth S, Esdaile JM, Beaulieu A, Zummer M, Senécal JL, Goulet JR, Choquette D, Rich E, Smith D, Cividino A, Gladman D, St-Pierre Y, Clarke AE: Counterbalancing patient demands with evidence: results from a pan-Canadian randomized clinical trial of brief supportive-expressive group psychotherapy for women with systemic lupus erythematosus. Ann Behav Med 2002;24:88–99.
  44. Kissane DW, Grabsch B, Clarke DM, Smith GC, Love AW, Bloch S, Snyder RD, Li Y: Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology 2007;16:277–286.
  45. Weiss JJ, Mulder CL, Antoni MH, de Vroome EMM, Garssen B, Goodkin K: Effects of a supportive-expressive group intervention on long-term psychosocial adjustment in HIV-infected gay men. Psychother Psychosom 2003;72:132–140.
  46. Kraaimaat FW, Brons MR, Geenen R, Bijlsma JWJ: The effect of cognitive behavior therapy in patients with rheumatoid arthritis. Behav Res Ther 1995;33:487–495.
  47. Savelkoul M, de Witte L, Post M: Stimulating active coping in patients with rheumatic diseases: a systematic review of controlled group intervention studies. Patient Educ Couns 2003;50:133–143.
  48. Sharpe L, Allard S, Sensky T: Five-year follow-up of a cognitive-behavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum 2008;59:311–316.
  49. Doeglas DM, Suurmeijer TPBM, van den Heuvel WJA, Krol B, van Rijswijk MH, van Leeuwen MA, Sanderman R: Functional ability, social support, and depression in rheumatoid arthritis. Qual Life Res 2004;13:1053–1065.
  50. Smedstad LM, Vaglum P, Moum T, Kvien TK: The relationship between psychological distress and traditional clinical variables: a 2-year prospective study of 216 patients with early rheumatoid arthritis. Br J Rheumatol 1997;36:1304–1311.
  51. Dobkin PL, Filipski M, Looper K, Schieir O, Baron M, McGill Early Arthritis Research Group: Identifying target areas of treatment for depressed early inflammatory arthritis patients. Psychother Psychosom 2008;77:298–305.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50